leisure time -WSS

leisure time

author：knowledge 2025-10-02 21:04:50 - browse：2

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Illumina board agrees to spin off Grail, as divestment plans proceed

explore

WSS

CDC director unscathed in first congressional testimony

Medicare Advantage's lean provider networks lead CMS complaints

Sutter Health’s antitrust win overturned by appeals court

The EPA's new lead rule: How one expert crunched the numbers

Mayo Clinic plans $5B tech

J&J to emphasize cancer drugs, stop much of its vaccine research

explore

leisure time

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Structure Therapeutics oral GLP

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Takeda, Janssen join wearable maker to measure scratching

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Despite FDA concern, risk that CAR

Virginia high school admissions case could be legal follow

Senators tussle over abortion against the backdrop of a presidential campaign

Medical leaders decry Supreme Court decision on affirmative action

Diagnostic tests are hitting their mathematical limits

explore

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

What don’t we know about an Alzheimer’s drug side effect?

Despite FDA concern, risk that CAR

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Take antibiotics after sex, CDC recommends for certain risk groups

Take antibiotics after sex, CDC recommends for certain risk groups

explore

explore

focus

hotspot